Publications

Publications

Cyclacel has contributed to many scientific advancements.

Dec 2020

Kawakami M et al., A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis, and Metastasis in Aneuploid Cancers. Mol Cancer Ther. 2021, 20:477-489.


Oct 2020

Do KT et al, Phase 1 safety, pharmacokinetic and pharmacodynamic study of fadraciclib (CYC065), a cyclin-dependent kinase inhibitor, in patients with advanced cancers (NCT02552953). An oral presentation delivered at the 32nd EORTC/AACR/NCI Virtual Symposium 24-25 Oct 2020.


Oct 2020

Poon E et al., Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma. J Clin Invest 2020; https://doi.org/10.1172/JCI134132.


Aug 2020

Decker JT et al., Cyclin E overexpression confers resistance to trastuzumab through noncanonical phosphorylation of SMAD3 in HER2+ breast cancer. Cancer Biol & Therapy 2020; https://doi.org/10.1080/15384047.2020.1818518.


Jul 2020

Frame S et al., Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer. PLOS One, July 9, 2020; doi.org/10.1371/journal.pone.0234103.


Apr 2018

Chen R et al., Strategic combination of the cyclin-dependent kinase inhibitor CYC065 with venetoclax to target anti-apoptotic proteins in chronic lymphocytic leukemia. Proc. Ann. Meeting AACR, 2018, Apr 14-18; Chicago, IL, Abstract 3905.


Apr 2018

Do KT et al., Phase I safety, pharmacokinetic and pharmacodynamic study of CYC065, a cyclin-dependent kinase inhibitor, in patients with advanced cancers (NCT02552953). Proc. Ann. Meeting AACR, 2018, Apr 14-18; Chicago, IL, Abstract CT037.


Feb 2017

Kawakami M et al., Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer. J Natl Cancer Inst. 2017, 109(6): djw297.


Sep 2016

Poon E et al., The small molecule CDK2 and CDK9 inhibitors CYC065 and CCT68127 are potent inhibitors of MYCN via transcriptional repression. Childhood Cancer Meeting 2016, Sept 5–7, London, UK, Abstract 1-19.


Jun 2016

Cocco E et al., Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo. Br J Cancer 2016. 115:303-11.


Learn More About Our Science

Paul McBarron

Executive Vice President, Chief Financial Officer & Chief Operating Officer​

Mr. McBarron has served as a director of the Company since March 2006. Mr. McBarron joined Cyclacel in January 2002 and has over 30 years of experience with pharmaceutical and biotechnology companies. He has served as a financial executive at Sterling Drug, Sanofi-Winthrop and SmithKline Beecham and, from 1996 to 2001, as a senior member of the finance team at Shire Pharmaceuticals plc, where he held the positions of Director of Corporate Finance and Group Financial Controller. He joined Shire when it was an emerging public company. He qualified as a chartered accountant with Ernst & Young and served on the Scottish Lifesciences Association Board.